StockData

MeiraGTx vs Regenxbio

MGTX and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGTX and RGNX compare

MeiraGTx is the larger company, worth 1.7 times as much as Regenxbio ($839M against $483M).

MeiraGTx grew revenue faster over the last twelve months (948% versus 12.0% for Regenxbio).

MeiraGTx keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with −113% at Regenxbio.

MeiraGTx scores higher on the StockData Score (13 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGTXRGNX
Size and price
Market cap$839M$483M
Share price$8.74$7.32
Change, 1 year5.8%−37.1%
Change, 5 years−51.3%−76.4%
Beta (5Y)2.092.62
Employees403371
StockData Score
Total score13 (better)4
Valuation score4 (better)0
Growth score22
Performance score4 (better)1
Health score3 (better)1
Dividend score00
Valuation
P/E12.3×–
P/S2.1× (better)2.8×
P/B–6.7×
EV/EBITDA4.1×–
P/FCF80.2×–
FCF yield1.2% (better)−51.7%
Fair value$24.59–
Margin of safety64.5%–
Growth
Revenue growth (TTM)948% (better)12.0%
Revenue growth, 5Y average39.2% (better)2.0%
Profitability
Operating margin46.3% (better)−94.1%
Net margin19.9% (better)−113%
FCF margin2.6% (better)−143%
Return on equity2668% (better)−138%
Return on invested capital344%–
Financial health
Net debt / EBITDA−0.22–
Interest coverage14.7× (better)−3.9×
Current ratio3.76 (better)2.86
Altman Z-score3.33 (better)−3.87
Piotroski F-score44
Dividends and buybacks
Buyback yield−15.9%–
Shareholder yield−15.9%0.00% (better)
Ownership
Held by institutions82.5%64.2%
Held by insiders35.2%7.6%
Insider net buying, 12 months−$4.7M$9.6K (better)
Short interest, % of float10.7%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.